Concordance Assessment of Self-Reported Medication Use in the Netherlands Three- Generation Lifelines Cohort Study with the Phar
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Characterising the Risk of Major Bleeding in Patients With
EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods .................................................................................................................... -
Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11. -
Summary of Product Characteristics
Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Audaval 0.1% Ointment 2 QUALITATIVE AND QUANTITATIVE COMPOSITION One gram of ointment contains 1 mg of betamethasone (0.1% w/w) as valerate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Ointment Opaque ointment. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Audaval preparations are indicated for the treatment of: eczema in children over 1 year elderly and adults; including atopic and discoid eczemas; prurigo nodularis; psoriasis (excluding widespread plaque psoriasis); neurodermatoses, including lichen simplex, lichen planus; seborrhoeic dermatitis; contact sensitivity reactions; discoid lupus erythematosus and they may be used as an adjunct to systemic steroid therapy in generalised erythroderma. In general, ointment preparations are particularly appropriate for dry, lichenified or scaly skin conditions whereas a cream preparation may be more suitable in the case of moist or weeping lesions. 4.2 Posology and method of administration For topical use only. If no improvement is seen after two to four weeks, the diagnosis should be reconsidered and specialist referral may be necessary. Adults, adolescents and the elderly A small quantity of Audaval should be applied to the affected area one to three times daily as directed by physician until improvement occurs. It may then be possible to maintain improvement by applying once a day, or even less often, or by using the appropriate ready diluted (1 in 4) preparation, Audaval RD 0.025% Ointment. Allow adequate time for absorption after each application before applying an emollient. If no improvement is seen within two to four weeks, reassessment of the diagnosis, or referral, may be necessary. -
Endogenous Metabolites in Drug Discovery: from Plants to Humans
Endogenous Metabolites in Drug Discovery: from Plants to Humans Joaquim Olivés Farrés TESI DOCTORAL UPF / ANY 201 6 DIRECTOR DE LA TESI: Dr. Jordi Mestres CEXS Department The research in this T hesis has been carried out at the Systems Pharmacolo gy Group , within the Research Programme on Biomedical Informatics (GRIB) at the Parc de Recerca Biomèdica de Barcelona (PRBB). The research presented in this T hesis has been supported by Ministerio de Ciencia e Innovación project BIO2014 - 54404 - R and BIO2011 - 26669 . Printing funded by the Fundació IMIM’s program “Convocatòria d'ajuts 2016 per a la finalització de tesis doctorals de la Fundació IMIM.” Agraïments Voldria donar les gràcies a tanta gent que em fa por deixar - me ningú. Però per c omençar haig agrair en especial al meu director la tesi, Jordi Mestres, per donar - me la oportunitat de formar part del seu laboratori i poder desenvolupar aquí el treball que aquí es presenta. A més d’oferir l’ajuda necessària sempre que ha calgut. També haig de donar les gràcies a tots els companys del grup de Farmacologia de Sistemes que he anat coneguent durants tots aquests anys en què he estat aquí, en especial en Xavi, a qui li he preguntat mil coses, en Nikita, pels sdfs que m’ha anat llençant a CTL ink, i la Irene i la Cristina, que els seus treballs també m’ajuden a completar la tesis. I cal agrair també a la resta de companys del laboratori, l’Albert, la Viktoria, la Mari Carmen, l’Andreas, en George, l’Eric i l’Andreu; de Chemotargets, en Ricard i en David; i altres membres del GRIB, com són l’Alfons, en Miguel, en Pau, l’Oriol i la Carina. -
ICD-10 International Statistical Classification of Diseases and Related Health Problems
ICD-10 International Statistical Classification of Diseases and Related Health Problems 10th Revision Volume 2 Instruction manual 2010 Edition WHO Library Cataloguing-in-Publication Data International statistical classification of diseases and related health problems. - 10th revision, edition 2010. 3 v. Contents: v. 1. Tabular list – v. 2. Instruction manual – v. 3. Alphabetical index. 1.Diseases - classification. 2.Classification. 3.Manuals. I.World Health Organization. II.ICD-10. ISBN 978 92 4 154834 2 (NLM classification: WB 15) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. -
Estonian Statistics on Medicines 2016 1/41
Estonian Statistics on Medicines 2016 ATC code ATC group / Active substance (rout of admin.) Quantity sold Unit DDD Unit DDD/1000/ day A ALIMENTARY TRACT AND METABOLISM 167,8985 A01 STOMATOLOGICAL PREPARATIONS 0,0738 A01A STOMATOLOGICAL PREPARATIONS 0,0738 A01AB Antiinfectives and antiseptics for local oral treatment 0,0738 A01AB09 Miconazole (O) 7088 g 0,2 g 0,0738 A01AB12 Hexetidine (O) 1951200 ml A01AB81 Neomycin+ Benzocaine (dental) 30200 pieces A01AB82 Demeclocycline+ Triamcinolone (dental) 680 g A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+ Thymol (dental) 3094 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+ Cetylpyridinium chloride (gingival) 227150 g A01AD81 Lidocaine+ Cetrimide (O) 30900 g A01AD82 Choline salicylate (O) 864720 pieces A01AD83 Lidocaine+ Chamomille extract (O) 370080 g A01AD90 Lidocaine+ Paraformaldehyde (dental) 405 g A02 DRUGS FOR ACID RELATED DISORDERS 47,1312 A02A ANTACIDS 1,0133 Combinations and complexes of aluminium, calcium and A02AD 1,0133 magnesium compounds A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 811120 pieces 10 pieces 0,1689 A02AD81 Aluminium hydroxide+ Magnesium hydroxide (O) 3101974 ml 50 ml 0,1292 A02AD83 Calcium carbonate+ Magnesium carbonate (O) 3434232 pieces 10 pieces 0,7152 DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 46,1179 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 2,3855 A02BA02 Ranitidine (O) 340327,5 g 0,3 g 2,3624 A02BA02 Ranitidine (P) 3318,25 g 0,3 g 0,0230 A02BC Proton pump inhibitors 43,7324 A02BC01 Omeprazole -
Antiphlogistika / Antirheumatika Systemisch (ATC-Code: M01*)
Wirkstoffziele Stand: 10. Juni 2020 iStockphoto.com/Krasyuk Eine Information der Kassenärztlichen Vereinigung Bayerns . [email protected] . www.kvb.de/verordnungen Wirkstoffgruppe: Antiphlogistika / Antirheumatika systemisch (ATC-Code: M01*) Ziel 8: Generika möglichst mit Rabattvertrag verordnen! Erläuterung Die häufigsten Verordnungen aus dieser Wirkstoffgruppe fallen auf die systemischen nicht steroidalen Antiphlogistika (NSAR). Daneben werden Arzneimittel mit den Wirkstoffen Me- thotrexat und Sulfasalazin in dieser Wirkstoffgruppe erfasst. Auch das u. a. als Antidot eingesetzte Penicillamin wird dem ATC-Code M01 zugeordnet. Maßnahmen zur Umsetzung Nichtselektive Antiphlogistika wie Ibuprofen, Naproxen und Diclofenac sind die Therapie der Wahl und stehen generisch und mit vielen Rabattverträgen zur Verfügung. Die Therapie mit Diclofenac ist allerdings mit einem erhöhten Risiko arterieller thrombotischer Ereignisse as- soziiert (vgl. Rote Hand Brief vom Juli 2013). Bei den Ibuprofen Kinderzäpfchen wurden bis- her keine Rabattverträge geschlossen, bei den Kindersäften hingegen hat nur die AOK Bay- ern keinen Rabattvertrag mehr. Für die Wirkstoffe Naproxen und Diclofenac lassen sich überall Rabattverträge finden, beim Diclofenac allerdings nicht immer für die parenterale An- wendung, die ohnehin nur in Ausnahmefällen gewählt werden sollte. Zur Behandlung von Symptomen bei Reizzuständen degenerativer Gelenkerkrankungen (aktivierter Arthrose) und chronischer Polyarthritis (rheumatoider Arthritis) gibt es generi- sches Celecoxib und Etoricoxib mit flächendeckend Rabattverträgen im Markt. Das nur pa- renteral einsetzbare Parecoxib trägt als Altoriginal ohne Rabattvertrag (Dynastat®) kaum zur Zielerreichung bei. Kardiovaskuläre Risiken sind als ein Klasseneffekt der Coxibe zu sehen, deshalb sind vor einer Verordnung unbedingt die Kontraindikationen zu beachten. Die Einnahme von NSAR geht mit einem deutlichen Risiko für Komplikationen im oberen Gastrointestinaltrakt einher – dies gilt auch für die Coxibe. -
(CNAM-TS) Database
Manoj Sharma et al. / Journal of Pharmacy Research 2012,5(9),4893-4896 Research Article Available online through ISSN: 0974-6943 http://jprsolutions.info Use of NSAIDs in France: Analysis from French reimbursement (CNAM-TS) database Manoj Sharma1*, Sinem E. Gulmez2, Régis Lassalle3, Nicholas Moore4 1Research Fellow. INSERM U657 Pharmaco-Epidémiologie, Service de Pharmacologie, Université de Bordeaux, Bordeaux, France. Manager, Global Pharmacovigilance Deptt. Panacea Biotec Ltd. New Delhi,India 2Associate Professor of Pharmacology, M.D., PhD. INSERM CIC-P 0005 Pharmaco-Epidémiologie, Service de Pharmacologie, Université de Bordeaux, Bordeaux, France. 3Statistician and Database Manager, INSERM CIC-P 0005 Pharmaco-Epidémiologie, Service de Pharmacologie, Université de Bordeaux, Bordeaux, France. 4Professor of Clinical Pharmacology, MD, PhD, FRCP(Edin), FISPE. INSERM CIC-P 0005 Pharmaco-Epidémiologie, Service de Pharmacologie, Université de Bordeaux, Bordeaux, France. Received on:07-06-2012; Revised on: 18-07-2012; Accepted on:25-08-2012 ABSTRACT Background: Reimbursement databases provide indirect data regarding drug use or its exposure. In France, approximately 85% of the general population is covered by the national health insurance system (Caisse Nationale d’ Assurance Maladie des Travaileurs Salariés (CNAM-TS), which reimburses prescribed drugs and other medical expenses to salaried persons and families. Since analysis of reimbursement databases ensures that the prescribed drugs have at least been dispensed, even if not used, the present study was conducted to assess the utilization pattern of nimesulide and other NSAIDs in French population from reimbursement database (CNAM-TS). Method: Reimbursement data of NSAIDs (ATC code M01) were extracted from CNAM-TS database for the period 2002-2007. The defined daily doses (DDDs) were calculated from the number and size of packages of each NSAID and the different NSAIDs were ranked on the basis of total defined daily doses prescribed. -
Outcome of Upper Gastro-Intestinal Bleeding and Use of Ibuprofen Versus Article Research Paracetamol
Outcome of upper gastro-intestinal bleeding and use of ibuprofen versus Research article paracetamol • William J. Blot, Thomas Fischer, Gunnar Lauge Nielsen, Søren Friis, Michael Mumma, Loren Lipworth, Raymond DuBois, Joseph K. McLaughlin and Henrik T. Sørensen Introduction Pharm World Sci 2004; 26: 319–323. © 2004 Kluwer Academic Publishers. Printed in the Netherlands. It has been known for over a decade that use of nons- teroidal anti-inflammatory drugs (NSAIDs) can result W.J. Blot, M. Mumma, L. Lipworth, J.K. McLaughlin: in increased risk of upper gastro-intestinal bleeding International Epidemiology Institute, Rockville, Maryland, USA 1-3 R. Dubois: Vanderbilt University Medical Center, Nashville, (UGIB) . Numerous epidemiologic studies have doc- Tennessee, USA umented that rates of UGIB are elevated (about four- T. Fisher, G.L. Nielsen: Department of Clinical Epidemiology, fold on average) among persons taking aspirin and Aarhus and Aalborg University Hospitals, Aalborg, Denmark 1-3 H.T. Sørensen (correspondence, e-mail: [email protected]): non-aspirin NSAIDs . Variation in risk with the dose Department of Clinical Epidemiology, Aarhus; Aalborg and type of medication has been shown, but all forms University Hospitals, Aalborg, and Medical Department V, and doses appear to result in some elevation in risk1–3. Aarhus University Hospital, Aarhus, Denmark T. Fischer: Department of Cardiology, Aalborg University What is less clear is whether NSAID-related UGIB Hospital, Aalborg, Denmark differs in severity from non-NSAID-related UGIB, with G.L.Nielsen: Department of Gastroenterology, Aalborg the few outcome studies producing conflicting University Hospital, Aalborg, Denmark 4–12 S. Friis: Danish Cancer Society, Copenhagen, Denmark results . -
The Nurofen Plus Data Sheet
NEW ZEALAND DATA SHEET NUROFEN PLUS 1. TRADE NAME OF THE MEDICINAL PRODUCT NUROFEN PLUS Ibuprofen 200mg Codeine Phosphate Hemihydrate 12.8mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains ibuprofen 200.0 mg and codeine phosphate hemihydrate 12.8 mg. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet, film-coated NUROFEN PLUS is a white film coated, biconvex capsule-shaped tablet embossed with the logo ‘N+’ on one side. 4. CLINICAL PARTICULARS 4.1 Therapeutic Indications For the temporary relief of strong pain and or inflammation associated with headache (including migraine and tension headache), period pain, dental pain, back pain, neuralgia, rheumatic and arthritic, and muscular pain. 4.2 Posology and Method of Administration Posology: Codeine should be used at the lowest effective dose for the shortest period of time. This dose may be taken every 4 to 6 times daily as necessary. The maximum daily dose should not exceed 6 tablets in 24 hours. The duration of treatment should be limited to 3 days and if no effective pain relief is achieved the patients/carers should be advised to seek the views of a physician. Excessive use can be harmful. Codeine can cause addiction Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). Nurofen Plus - 12 October 2020 Adults, the elderly and children over 12 years; Initial dose, two tablets taken with fluid, then one to two tablets every 4 to 6 hours as necessary. Maximum 6 tablets in a 24 hour period Children aged less than 12 years: Ibuprofen + Codeine combination solid dose strength products should not be used in children below the age of 12 years because of the risk of opioid toxicity due to the variable and unpredictable metabolism of codeine to morphine (see sections 4.3 & 4.4). -
Anatomical Classification Guidelines V2021 EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021
EPHMRA ANATOMICAL CLASSIFICATION GUIDELINES 2021 Anatomical Classification Guidelines V2021 "The Anatomical Classification of Pharmaceutical Products has been developed and maintained by the European Pharmaceutical Marketing Research Association (EphMRA) and is therefore the intellectual property of this Association. EphMRA's Classification Committee prepares the guidelines for this classification system and takes care for new entries, changes and improvements in consultation with the product's manufacturer. The contents of the Anatomical Classification of Pharmaceutical Products remain the copyright to EphMRA. Permission for use need not be sought and no fee is required. We would appreciate, however, the acknowledgement of EphMRA Copyright in publications etc. Users of this classification system should keep in mind that Pharmaceutical markets can be segmented according to numerous criteria." © EphMRA 2021 Anatomical Classification Guidelines V2021 CONTENTS PAGE INTRODUCTION A ALIMENTARY TRACT AND METABOLISM 1 B BLOOD AND BLOOD FORMING ORGANS 28 C CARDIOVASCULAR SYSTEM 36 D DERMATOLOGICALS 51 G GENITO-URINARY SYSTEM AND SEX HORMONES 58 H SYSTEMIC HORMONAL PREPARATIONS (EXCLUDING SEX HORMONES) 68 J GENERAL ANTI-INFECTIVES SYSTEMIC 72 K HOSPITAL SOLUTIONS 88 L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS 96 M MUSCULO-SKELETAL SYSTEM 106 N NERVOUS SYSTEM 111 P PARASITOLOGY 122 R RESPIRATORY SYSTEM 124 S SENSORY ORGANS 136 T DIAGNOSTIC AGENTS 143 V VARIOUS 145 Anatomical Classification Guidelines V2021 INTRODUCTION The Anatomical Classification was initiated in 1971 by EphMRA. It has been developed jointly by Intellus/PBIRG and EphMRA. It is a subjective method of grouping certain pharmaceutical products and does not represent any particular market, as would be the case with any other classification system. -
Estonian Statistics on Medicines 2013 1/44
Estonian Statistics on Medicines 2013 DDD/1000/ ATC code ATC group / INN (rout of admin.) Quantity sold Unit DDD Unit day A ALIMENTARY TRACT AND METABOLISM 146,8152 A01 STOMATOLOGICAL PREPARATIONS 0,0760 A01A STOMATOLOGICAL PREPARATIONS 0,0760 A01AB Antiinfectives and antiseptics for local oral treatment 0,0760 A01AB09 Miconazole(O) 7139,2 g 0,2 g 0,0760 A01AB12 Hexetidine(O) 1541120 ml A01AB81 Neomycin+Benzocaine(C) 23900 pieces A01AC Corticosteroids for local oral treatment A01AC81 Dexamethasone+Thymol(dental) 2639 ml A01AD Other agents for local oral treatment A01AD80 Lidocaine+Cetylpyridinium chloride(gingival) 179340 g A01AD81 Lidocaine+Cetrimide(O) 23565 g A01AD82 Choline salicylate(O) 824240 pieces A01AD83 Lidocaine+Chamomille extract(O) 317140 g A01AD86 Lidocaine+Eugenol(gingival) 1128 g A02 DRUGS FOR ACID RELATED DISORDERS 35,6598 A02A ANTACIDS 0,9596 Combinations and complexes of aluminium, calcium and A02AD 0,9596 magnesium compounds A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 591680 pieces 10 pieces 0,1261 A02AD81 Aluminium hydroxide+Magnesium hydroxide(O) 1998558 ml 50 ml 0,0852 A02AD82 Aluminium aminoacetate+Magnesium oxide(O) 463540 pieces 10 pieces 0,0988 A02AD83 Calcium carbonate+Magnesium carbonate(O) 3049560 pieces 10 pieces 0,6497 A02AF Antacids with antiflatulents Aluminium hydroxide+Magnesium A02AF80 1000790 ml hydroxide+Simeticone(O) DRUGS FOR PEPTIC ULCER AND GASTRO- A02B 34,7001 OESOPHAGEAL REFLUX DISEASE (GORD) A02BA H2-receptor antagonists 3,5364 A02BA02 Ranitidine(O) 494352,3 g 0,3 g 3,5106 A02BA02 Ranitidine(P)